TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
B: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Participants; Type: N/A; Interventions: N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Brief Summary: The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require immediate correction of international normalized ratio (INR) because of emergency surgery.


Options:
A: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
B: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
C: Arm Label: Coagulation factor concentrates; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate | Arm Label: Fresh Frozen Plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh Frozen Plasma blood type 0, A, B and AB | Intervention Type: DRUG; Name: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate; Assigned to Arm(s): Coagulation factor concentrates | Intervention Type: DRUG; Name: Fresh Frozen Plasma blood type 0, A, B and AB; Assigned to Arm(s): Fresh Frozen Plasma
D: Arm Label: FXIII17.5IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: FXIII35IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII17.5IU/Kg | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII35IU/Kg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Growth Hormone Therapy for Wasting in Cystic Fibrosis
Brief Summary: Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life. We theorize that this will occur through a multitude of factors: increased appetite, more constructive utilization of caloric intake and decreased catabolic signaling. The first aim will address changes in weight and lean body mass following the institution of GH therapy in adults with Cystic Fibrosis (CF) related wasting. The second aim will measure impact on quality of life of these individuals. Additionally, the third aim will monitor effects of GH therapy on diabetes and insulin sensitivity. Finally, the fourth aim will observe changes in the subjects underlying diagnosis of CF, specifically lung function, muscle strength and inflammatory state.


Options:
A: Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin Asparte, Drug: Repaglinide | Intervention Type: DRUG; Name: Insulin Asparte; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): III
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2
C: Arm Label: Growth Hormone Therapy; Type: EXPERIMENTAL; Interventions: Drug: Nutropin AQ | Intervention Type: DRUG; Name: Nutropin AQ; Assigned to Arm(s): Growth Hormone Therapy
D: Arm Label: Telehealth; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Stress Management | Arm Label: Treatment-As-Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management; Assigned to Arm(s): Telehealth

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A specific type of mutation called a nonsense (premature stop codon) mutation is the cause of CF in approximately 10% of patients with the disease. Ataluren is an orally delivered investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 3 trial that will evaluate the clinical benefit of ataluren in adult and pediatric participants with CF due to a nonsense mutation. The main goals of the study are to understand whether ataluren can improve pulmonary function and whether the drug can safely be given for a long period of time. The study will also assess the effects of ataluren on CF pulmonary exacerbation frequency, cough frequency, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Treatment Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Arm Label: Treatment Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2
C: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part A: 3 to <24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Arm Label: Part B + A/B:1 to < 24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: 3 to <24 months, Part B + A/B:1 to < 24 months

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A specific type of mutation called a nonsense (premature stop codon) mutation is the cause of CF in approximately 10% of patients with the disease. Ataluren is an orally delivered investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 3 trial that will evaluate the clinical benefit of ataluren in adult and pediatric participants with CF due to a nonsense mutation. The main goals of the study are to understand whether ataluren can improve pulmonary function and whether the drug can safely be given for a long period of time. The study will also assess the effects of ataluren on CF pulmonary exacerbation frequency, cough frequency, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology.


Options:
A: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg
B: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO
C: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren
D: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial
Brief Summary: The purpose of this study is to find out how long it takes the vagina to respond to hormonal vaginal cream in women with pelvic organ prolapse (bulge in the vagina). It also will address the appropriate amount to use prior to vaginal repair of pelvic organ prolapse.


Options:
A: Arm Label: Pessary Check at 3 months; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 6 month Pessary Check; Type: EXPERIMENTAL; Interventions: Other: 6 month follow up for pessary check in the clinic setting | Intervention Type: OTHER; Name: 6 month follow up for pessary check in the clinic setting; Assigned to Arm(s): 6 month Pessary Check
B: Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Premarin vaginal cream | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo cream | Intervention Type: DRUG; Name: Premarin vaginal cream; Assigned to Arm(s): Treatment group | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Control group
C: Arm Label: Premarin cream 0.5gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 0.5gm | Arm Label: Premarin cream 1.0gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 1.0gm | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 0.5gm; Assigned to Arm(s): Premarin cream 0.5gm | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 1.0gm; Assigned to Arm(s): Premarin cream 1.0gm
D: Arm Label: Intravaginal Pessary; Type: EXPERIMENTAL; Interventions: Device: Intravaginal Pessary | Arm Label: Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy | Arm Label: Pessary combined with behavioral therapy; Type: EXPERIMENTAL; Interventions: Device: Pessary combined with behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Behavioral Therapy | Intervention Type: DEVICE; Name: Intravaginal Pessary; Assigned to Arm(s): Intravaginal Pessary | Intervention Type: DEVICE; Name: Pessary combined with behavioral therapy; Assigned to Arm(s): Pessary combined with behavioral therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.
Brief Summary: This study is to look at a new formulation of GSK573719 to see if it is safe and tolerated in healthy volunteers


Options:
A: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: 100mcg | Arm Label: Active 2; Type: EXPERIMENTAL; Interventions: Drug: 500mcg | Arm Label: Active 3; Type: EXPERIMENTAL; Interventions: Drug: 1000mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 100mcg; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: 500mcg; Assigned to Arm(s): Active 2 | Intervention Type: DRUG; Name: 1000mcg; Assigned to Arm(s): Active 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 4; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Intervention Type: DRUG; Name: FF 400 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 500 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 250 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: VI 100 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Urodynamic Testing Before Stress-Incontinence Surgery
Brief Summary: Although no reliable and specific figures are available for the total expenditure on UDS, UDS is commonly performed for patients with urinary incontinence (UI) regardless of gender and age. UDS is typically performed prior to incontinence surgery. Urodynamic studies are expensive, time-consuming, and uncomfortable diagnostic investigations. The 3rd ICI reported insufficient evidence with which to answer the following key research questions related to UDS: 1) Do physicians alter clinical decision-making based on results of UDS?, and 2) Do alterations in clinical decisions made in response to UDS results improve the clinical outcomes?


Options:
A: Intervention Type: DRUG; Name: SS-RBX; Assigned to Arm(s): N/A
B: Arm Label: No UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation | Arm Label: UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation, Other: UDS | Intervention Type: OTHER; Name: Office evaluation; Assigned to Arm(s): No UDS, UDS | Intervention Type: OTHER; Name: UDS; Assigned to Arm(s): UDS
C: Intervention Type: PROCEDURE; Name: Urodynamics; Assigned to Arm(s): N/A
D: Arm Label: surgical therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: midureteral sling | Arm Label: individual management; Type: ACTIVE_COMPARATOR; Interventions: Other: surgical therapy or conservative | Intervention Type: PROCEDURE; Name: midureteral sling; Assigned to Arm(s): surgical therapy | Intervention Type: OTHER; Name: surgical therapy or conservative; Assigned to Arm(s): individual management

Answer: B